Skip to main content
. 2018 Oct 17;8:15331. doi: 10.1038/s41598-018-32853-w

Figure 6.

Figure 6

Imatinib lowers pro-inflammatory activation in human monocytes, but hyperglycemia alters their responsiveness. (a,b) Fold change gene expression of TNFα, MCP-1 and CD163 in human M0- (a) or M1-monocytes (b) treated with 1 μM of imatinib (M0 + IM or M1 + IM, open bars) compared to non-treated M0- or M1-monocytes (M0 or M1, closed bar) from healthy controls (He, n = 6), adequately controlled diabetics (aDM, n = 5) and inadequately controlled diabetics (iaDM, n = 5). (c) Fold change of gene expression of TNFα, MCP-1 and CD163 with increasing doses of imatinib (1, 2.5, 5 μM) in inadequately controlled diabetics (n = 3). Data expressed as mean ± SEM, *p < 0.05, **p < 0.01.